Why the study?
Recognizing endocrine etiologies of cardiomyopathy is crucial because targeted hormonal therapies can reverse or significantly mitigate cardiac dysfunction, making comprehensive endocrine screening essential.
Recognizing endocrine etiologies in unexplained cardiomyopathy is crucial because targeted therapies can reverse cardiac dysfunction and prevent progression to irreversible heart failure.
Answers are grounded in this paper and cite their sources.
May support endocrine screening in unexplained cardiomyopathy; leaves open prospective validation of reversal.
insulin-like growth factor 1 overproduction. Pheochromocytoma triggers catecholamine-induced cardiomyopathy, resembling Takotsubo syndrome and carrying a high risk of mortality if left untreated. Diabetes induces a distinct phenotype of cardiomyopathy, affecting both systolic and diastolic function through microvascular injury and oxidative stress. Recognizing these endocrine etiologies is crucial, as targeted hormonal therapies-such as antithyroid agents, somatostatin analogs, or adrenalectomy-can reverse or significantly mitigate cardiac dysfunction. Comprehensive endocrine screening in patients with unexplained cardiomyopathy is therefore essential. This review synthesizes current knowledge on the pathophysiological mechanisms, clinical manifestations, and therapeutic strategies for endocrine cardiomyopathies and proposes a diagnostic algorithm for early recognition. Emerging biomarkers, such as galectin-3 in diabetic heart disease, may further enhance diagnostic accuracy and risk stratification. The interplay between endocrine and cardiovascular systems offers a unique opportunity for early intervention, potentially preventing progression to irreversible HF.
No takes yet. Share an insight, caveat, or question.
Fuentes‐Mendoza et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: